MADRIGAL PHARMACEUTICA

336,74

26-ноября-24 16:45:00

15 мин. задержка

Акции

-8,44

-2,45%

Сегодняшний диапазон

329,67 - 347,06

ISIN

N/A

Источник

NASDAQ

NetDania - New 12 months High: MADRIGAL PHARMACEUTICALS INC. - COMMON STOCK

07 ноя 2024 11:24:15 Источник NetDania Notify
NetDania - New 12 months High: MADRIGAL PHARMACEUTICALS INC. - COMMON STOCK

06 ноя 2024 09:45:20 Источник NetDania Notify
Madrigal Pharmaceuticals, Inc. Announces Participation at Three Upcoming Investor Conferences

06 ноя 2024 08:00:00 Источник Nasdaq GlobeNewswire
NetDania - New 12 months High: MADRIGAL PHARMACEUTICALS INC. - COMMON STOCK

05 ноя 2024 16:15:01 Источник NetDania Notify
NetDania - New 12 months High: MADRIGAL PHARMACEUTICALS INC. - COMMON STOCK

04 ноя 2024 09:47:38 Источник NetDania Notify
NetDania - New 12 months High: MADRIGAL PHARMACEUTICALS INC. - COMMON STOCK

01 ноя 2024 10:37:32 Источник NetDania Notify
Madrigal Pharmaceuticals Reports Third-Quarter 2024 Financial Results and Provides Corporate Updates

31 окт 2024 07:00:01 Источник Nasdaq GlobeNewswire
Madrigal Pharmaceuticals to Present Multiple Rezdiffra™ (resmetirom) Abstracts in NASH/MASH at the AASLD Liver Meeting®

30 окт 2024 08:00:22 Источник Nasdaq GlobeNewswire
Madrigal Pharmaceuticals Completes Enrollment of Clinical Outcomes Study of Resmetirom in Patients with Compensated NASH/MASH Cirrhosis

21 окт 2024 08:00:00 Источник Nasdaq GlobeNewswire
Madrigal Pharmaceuticals to Release Third-Quarter 2024 Financial Results and Host Webcast on October 31, 2024

18 окт 2024 08:00:00 Источник Nasdaq GlobeNewswire
Madrigal Pharmaceuticals to Participate in the H.C. Wainwright & Co. 8th Annual MASH Investor Conference

02 окт 2024 08:00:00 Источник Nasdaq GlobeNewswire
Madrigal Pharmaceuticals Appoints Dr. Michael R. Charlton as Senior Vice President, Clinical Development

01 окт 2024 08:00:01 Источник Nasdaq GlobeNewswire
Madrigal Pharmaceuticals Announces Publication of Positive Health-Related Quality of Life Results from the Phase 3 MAESTRO-NASH Trial of Rezdiffra™ (resmetirom)

30 сен 2024 08:00:00 Источник Nasdaq GlobeNewswire
Madrigal Pharmaceuticals, Inc. to Participate in the Morgan Stanley 22nd Annual Global Healthcare Conference

26 авг 2024 08:00:00 Источник Nasdaq GlobeNewswire
Madrigal Pharmaceuticals Reports Second-Quarter 2024 Financial Results and Provides Corporate Updates

07 авг 2024 07:00:00 Источник Nasdaq GlobeNewswire
Madrigal Pharmaceuticals Appoints Shannon Kelley as General Counsel

02 авг 2024 07:00:21 Источник Nasdaq GlobeNewswire
Madrigal Pharmaceuticals to Release Second-Quarter 2024 Financial Results and Host Webcast on August 7, 2024

24 июл 2024 08:00:00 Источник Nasdaq GlobeNewswire
Madrigal Pharmaceuticals Announces New Data from the Phase 3 MAESTRO-NASH Study of Rezdiffra™ (resmetirom) Presented at the EASL Congress

06 июн 2024 08:00:00 Источник Nasdaq GlobeNewswire
Madrigal Pharmaceuticals to Present Multiple Rezdiffra™ (resmetirom) and Health Economics Outcomes Research Abstracts in NASH/MASH at the EASL Congress

29 май 2024 08:00:00 Источник Nasdaq GlobeNewswire
Madrigal Pharmaceuticals Reports First-Quarter 2024 Financial Results and Provides Corporate Updates

07 май 2024 07:00:01 Источник Nasdaq GlobeNewswire

<<
<
1
>

Принимаю NetDania's website uses cookies. By continuing browsing our website, you agree to our Правила в отношении Cookies, Политика конфиденциальности and Правила и условия.